Showing results (11-20 of 93) with videos related to
Sort By:
Pageof 10
Respiratory Investigation|December 12, 2018
Combination therapy with carboplatin and paclitaxel for small cell lung cancerAtsuto Mouri, Ou Yamaguchi, Sachiko Miyauchi, et al.Translational Lung Cancer Research|June 19, 2025
Prognostic factors of liver metastases in extensive-stage small cell lung cancer receiving chemo-immunotherapyKyoichi Kaira, Yuhei Kurata, Hisao Imai, et al.Translational Lung Cancer Research|May 19, 2025
Metabolic tumor volume on 18F-FDG uptake as a negative predictor after ipilimumab plus nivolumab in advanced non-small cell lung cancerKosuke Hashimoto, Kyoichi Kaira, Atsuto Mouri, et al.Cureus|January 6, 2025
Concurrent Onset of Osimertinib-Induced Heart Failure and Metronidazole-Induced Encephalopathy During Brain Abscess Treatment: A Report of a Rare CaseEmi Mikami, Kosuke Hashimoto, Kyoichi Kaira, et al.Oncology|September 19, 2023
Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung CancerOu Yamaguchi, Kyoichi Kaira, Hisao Imai, et al.Cancer Chemotherapy and Pharmacology|November 10, 2019
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutationOu Yamaguchi, Kyoichi Kaira, Atsuto Mouri, et al.Journal of Clinical Medicine|August 27, 2021
Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade DrugsAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.Translational Lung Cancer Research|May 22, 2026
TROP2 expression as a prognostic predictor for osimertinib in patients with EGFR-mutant non-small cell lung cancerNaohito Hashimoto, Kyoichi Kaira, Hisao Imai, et al.Cancers|April 13, 2024
Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by DurvalumabAtsuto Mouri, Satoshi Watanabe, Takaaki Tokito, et al.International Journal of Clinical Oncology|December 31, 2023
Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancerAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.Pageof 10